HomeCompareHSKA vs ARCC

HSKA vs ARCC: Dividend Comparison 2026

HSKA yields 0.25% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARCC wins by $4.5K in total portfolio value
10 years
HSKA
HSKA
● Live price
0.25%
Share price
$119.99
Annual div
$0.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$25.41
Full HSKA calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — HSKA vs ARCC

📍 ARCC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHSKAARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HSKA + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HSKA pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HSKA
Annual income on $10K today (after 15% tax)
$21.25/yr
After 10yr DRIP, annual income (after tax)
$21.60/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, HSKA beats the other by $20.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HSKA + ARCC for your $10,000?

HSKA: 50%ARCC: 50%
100% ARCC50/50100% HSKA
Portfolio after 10yr
$22.3K
Annual income
$13.28/yr
Blended yield
0.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

HSKA
Analyst Ratings
8
Buy
8
Hold
Consensus: Buy
Price Target
$159.50
+32.9% upside vs current
Range: $149.00 — $170.00
Altman Z
4.8
Piotroski
3/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HSKA buys
0
ARCC buys
0
No recent congressional trades found for HSKA or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHSKAARCC
Forward yield0.25%10.65%
Annual dividend / share$0.30$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$20.0K$24.5K
Annual income after 10y$25.41$1.14
Total dividends collected$252.00$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$159.50$21.88

Year-by-year: HSKA vs ARCC ($10,000, DRIP)

YearHSKA PortfolioHSKA Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$10,725$25.00$11,373$532.74$648.00ARCC
2$11,501$25.06$12,608$279.46$1.1KARCC
3$12,331$25.12$13,809$142.90$1.5KARCC
4$13,219$25.17$15,042$72.20$1.8KARCC
5$14,170$25.21$16,341$36.27$2.2KARCC
6$15,187$25.26$17,732$18.18$2.5KARCC
7$16,275$25.30$19,231$9.10$3.0KARCC
8$17,440$25.34$20,851$4.55$3.4KARCC
9$18,686$25.38$22,605$2.28$3.9KARCC
10$20,020$25.41$24,504$1.14$4.5KARCC

HSKA vs ARCC: Complete Analysis 2026

HSKAStock

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was founded in 1988 and is based in Loveland, Colorado.

Full HSKA Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this HSKA vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HSKA vs SCHDHSKA vs JEPIHSKA vs OHSKA vs KOHSKA vs MAINHSKA vs HTGCHSKA vs GBDCHSKA vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.